<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immunotherapy for the prevention and treatment of relapse following allogeneic hematopoietic cell transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immunotherapy for the prevention and treatment of relapse following allogeneic hematopoietic cell transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Immunotherapy for the prevention and treatment of relapse following allogeneic hematopoietic cell transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Negrin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson J Chao, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most patients who undergo allogeneic hematopoietic cell transplantation (HCT) for a hematologic malignancy attain a complete remission, but relapse occurs in 10 to 40 percent of patients.</p><p>Donor lymphocyte infusion (DLI), immune checkpoint inhibitors, and chimeric antigen receptor T cells (CAR-T cells) are important immunotherapy approaches for managing relapse after allogeneic HCT. Various cell therapies and vaccination are among the experimental immunotherapeutic strategies that are undergoing investigation in this setting.</p><p>This topic discusses immunotherapy to prevent and/or treat relapse following allogeneic HCT.</p><p>Management of relapse of specific hematologic malignancies following HCT is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4540.html" rel="external">"Treatment of relapsed or refractory acute myeloid leukemia", section on 'Relapse after HCT'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma", section on 'Second and subsequent relapses'</a>.)</p><p></p><p>Principles that underlie immunotherapy of graft-versus-tumor effect after HCT are presented separately. (See  <a class="medical medical_review" href="/z/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H909350729"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>The rationale for using immunotherapy to prevent and/or treat disease relapse after HCT is based on the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Graft-versus-tumor (GVT) effect reduces the risk of relapse following allogeneic HCT, as illustrated by higher rates of leukemia relapse in patients who have received identical twin (syngeneic) transplants compared with HLA-identical sibling transplants, despite identical cytotoxic treatment [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation", section on 'Identical twin donors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T cell-depleted grafts are associated with a higher incidence of disease relapse. (See  <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">"Prevention of graft-versus-host disease", section on 'T cell depletion (TCD)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who develop acute or chronic graft-versus-host disease have a lower risk of leukemia relapse [<a href="#rid2">2,3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Donor lymphocyte infusion (DLI) into patients who have relapsed following an allogeneic HCT induces GVT and can achieve remission with some diseases. (See <a class="local">'Donor lymphocyte infusion (DLI)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grafts with higher numbers of certain natural killer T cells (eg, iNKT cells) are associated with improved survival [<a href="#rid4">4-6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapse of acute myeloid leukemia after allogeneic HCT is associated with dysregulation of immune function pathways, including downregulation of MHC class II genes, which are involved in antigen presentation [<a href="#rid7">7</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">DONOR LYMPHOCYTE INFUSION (DLI)</span><span class="headingEndMark"> — </span>Donor lymphocyte infusion (DLI) can induce a graft-versus-tumor (GVT) effect and achieve complete and durable remissions in some patients who relapse after allogeneic HCT. DLI demonstrates the important role of GVT against hematologic malignancies. (See  <a class="medical medical_review" href="/z/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>DLI is primarily mediated by immune effector cells (<a class="graphic graphic_table graphicRef52815" href="/z/d/graphic/52815.html" rel="external">table 1</a>), including CD4+ T cells, CD8+ T cells, regulatory T cells (T regs), natural killer (NK) cells, and antigen presenting cells. Only rarely does reduction of immunosuppressive therapy without DLI achieve clinically meaningful GVT, and this effect may be limited to treatment of chronic myeloid leukemia (CML) [<a href="#rid8">8,9</a>].(See  <a class="medical medical_review" href="/z/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation"</a>.)</p><p>DLI is thought to mediate GVT primarily via reversal of T cell exhaustion in resident CD8+ T cells (a state of reduced effector function and proliferation by T cells associated with chronic antigen exposure) [<a href="#rid10">10,11</a>]. DLI is also associated with normalization of the T cell receptor repertoire and clonal expansion of allogeneic T cells and improved coordination of T and B cell immunity [<a href="#rid12">12,13</a>].</p><p>The targets of the GVT response are uncertain. Potential targets include disease-specific antigens (eg, BCR::ABL1 in chronic myeloid leukemia [CML], other leukemia-specific antigens, idiotypic immunoglobulins in plasma cell disorders), and nondisease-specific targets (eg, minor histocompatibility antigens), as listed in the accompanying table (<a class="graphic graphic_table graphicRef76786" href="/z/d/graphic/76786.html" rel="external">table 2</a>). </p><p>There is controversy about whether the GVT effect can be separated from graft-versus-host disease (GVHD). Experimental immunotherapy approaches that seek to separate GVT from GVHD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation", section on 'Possible separation of GVT from GVHD'</a>.)</p><p class="headingAnchor" id="H3970758926"><span class="h2">Time course of DLI response</span><span class="headingEndMark"> — </span>Patients who respond to DLI usually demonstrate a clinical response within two to three months, but a full response may take one year or longer [<a href="#rid14">14</a>]. Responses to DLI can be durable, with reports of responses lasting ≥20 years [<a href="#rid15">15</a>]. As an example, for patients with CML who achieved a molecular complete response (CR) in response to DLI, 95 percent were alive and in continuous CR at three years [<a href="#rid16">16</a>]. Similar results have been reported by others [<a href="#rid17">17-19</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Efficacy of DLI</span><span class="headingEndMark"> — </span>Efficacy of DLI varies with the type and amount of the underlying malignancy, dose and type of lymphocytes that are infused, and factors related to the initial allogeneic HCT.</p><p class="headingAnchor" id="H3994359382"><span class="h3">Disease effects</span><span class="headingEndMark"> — </span>Hematologic malignancies differ in their intrinsic sensitivity to GVT but, in general, relapse rates are lower in proportion to the severity of GVHD. A study that included nearly 50,000 patients who underwent allogeneic HCT reported the greatest sensitivity to GVHD for CML and <em>BCR::ABL1</em>-negative myeloproliferative neoplasms (eg, polycythemia vera, essential thrombocythemia, myelofibrosis), intermediate sensitivity for myelodysplastic neoplasms/syndromes (MDS), acute myeloid leukemia (AML), and lymphoproliferative disorders, and least sensitivity for acute lymphoblastic leukemia (ALL) and plasma cell disorders [<a href="#rid20">20</a>].</p><p>A review of responses to DLI based on the type of hematologic malignancy included the following estimates [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CML</strong> – Nearly 100 percent response in patients with molecular relapse of chronic phase CML, &gt;75 percent response with hematologic relapse of chronic phase CML, and lower response rates (eg, 12 to 35 percent) in accelerated or blast phase of CML.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AML</strong> – CR rates of 15 to 42 percent with two-year overall survival (OS) 15 to 20 percent at two years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ALL</strong> – CR rates of 18 to &gt;50 percent (although most patients also received chemotherapy) and two-year OS 5 to 20 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphomas</strong> – CR rates of 42 to 85 percent and two-year OS 35 to 70 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple myeloma</strong> – CR rates of 42 to 85 percent and two-year OS &gt;40 percent at two years.</p><p></p><p>DLI is effective for both clinical relapse and in the setting of lower disease burden (ie, molecular relapse). As an example, in a prospective study of allogeneic HCT for acute leukemia, DLI was administered to patients with measurable residual disease (MRD) following transplantation [<a href="#rid21">21</a>]. Those who received DLI achieved comparable clinical outcomes to patients who remained MRD negative, and both groups had superior outcomes compared to MRD-positive patients who were treated with IL-2 because there was no available donor for DLI.</p><p>Use of DLI for CML and AML is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4494.html" rel="external">"Hematopoietic cell transplantation in chronic myeloid leukemia", section on 'Donor lymphocyte infusion'</a> and  <a class="medical medical_review" href="/z/d/html/4540.html" rel="external">"Treatment of relapsed or refractory acute myeloid leukemia", section on 'Donor lymphocyte infusion'</a>.)</p><p class="headingAnchor" id="H975110267"><span class="h3">Dose and type of DLI</span><span class="headingEndMark"> — </span>DLI efficacy is influenced by the number and nature of infused cells.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – Published studies have reported doses ranging from 0.01 to 8.8 x 10<sup>8</sup> T cells/kg [<a href="#rid14">14</a>]. Cell doses &lt;0.01 x 10<sup>8</sup> T cells/kg appear to be suboptimal and doses &gt;4.5 x 10<sup>8</sup> T cells/kg do not appear to improve response and likely carry more risk for GVHD. (See <a class="local">'Clinical administration of DLI'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of infusion</strong> – Unmanipulated leukocytes can achieve significant clinical responses, particularly in patients with CML [<a href="#rid22">22</a>]. Donor source (ie, DLI from HLA-matched related donors versus matched unrelated donors) had no effect on the rates of durable molecular remission [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">The effect of donor source and manipulation of the infused cells on GVHD is discussed below. (See <a class="local">'GVHD'</a> below.)</p><p></p><p>Experimental methods of manipulating cells prior to infusion are discussed below. (See <a class="local">'Manipulated DLI grafts'</a> below.)</p><p class="headingAnchor" id="H2061282219"><span class="h3">Host effects</span><span class="headingEndMark"> — </span>Efficacy of DLI is influenced by host effects, including the intensity and type of conditioning, donor-recipient alloreactivity, T cell depletion of the host, timing of DLI, and post-transplantation immunosuppression therapy [<a href="#rid23">23,24</a>]. However, the direction and magnitude of these contributions to efficacy of DLI are not well defined and difficult to utilize clinically.</p><p>As an example, in one uncontrolled study, T cell depletion of the host with <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> conditioning or anti-thymocyte globulin was associated with a low rate of relapse [<a href="#rid25">25</a>]. In contrast, in another study, lymphodepletion of the host was associated with increased GVHD [<a href="#rid26">26</a>]. The presence of host-derived regulatory T cells was reported to be associated with decreased GVT effect [<a href="#rid27">27</a>].</p><p>DLI has been used successfully with both myeloablative and nonmyeloablative/reduced-intensity conditioning [<a href="#rid25">25,28</a>].</p><p class="headingAnchor" id="H1037110845"><span class="h2">Toxicity of DLI</span><span class="headingEndMark"> — </span>The major complications of DLI are GVHD and bone marrow hypoplasia.</p><p class="headingAnchor" id="H6"><span class="h3">GVHD</span><span class="headingEndMark"> — </span>GVHD is the most important adverse effect of DLI. Clinical manifestations of acute and chronic GVHD are described separately. (See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a>.)</p><p>Approximately 60 to 70 percent of patients receiving a DLI will develop GVHD [<a href="#rid29">29</a>]. DLI is likely to exacerbate ongoing GVHD. (See <a class="local">'Cautions regarding DLI'</a> below.)</p><p>Factors that may contribute to the incidence and severity of GVHD following DLI include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – Doses &gt;1 x 10<sup>8</sup> T cells/kg are associated with higher rates of GVHD [<a href="#rid14">14,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schedule</strong> – One study reported a lower rate of GVHD when using an escalating DLI cell dose regimen versus a single bulk infusion, but the two approaches achieved similar rates of remission [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manipulation of the graft</strong> – Depletion of CD8+ T cells or enrichment of CD4+ T cells may increase the rate of GVHD [<a href="#rid31">31,32</a>]. Depletion of naïve T cells and infusion of memory CD8+ cells may reduce the risk of GVHD; however, the impact on GVT reactions is less clear. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphodepletion</strong> – Lymphodepletion of the host prior to DLI (ie, use of a lymphodepleting HCT conditioning regimen) is associated with more acute GVHD and greater GVHD lethality [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease</strong> – The rate of GVHD appears to be independent of the underlying malignant disorder.</p><p></p><p>Other factors that may influence GVHD include donor-recipient HLA status, intensity of the conditioning regimen, degree of donor chimerism, and post-transplantation immunosuppression therapy [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Hypoplasia</span><span class="headingEndMark"> — </span>Bone marrow hypoplasia and/or aplasia after DLI has been reported in 20 to 40 percent of patients. Patients with aplasia have an overall mortality of about 5 percent due to infections or bleeding [<a href="#rid14">14</a>].</p><p>Aplasia has been reported primarily in patients with little or no evidence of ongoing donor hematopoiesis (measured by the presence of donor CD34+ cells) at the time of DLI [<a href="#rid33">33</a>]. Bone marrow chimerism should be evaluated prior to the possible use of DLI, as discussed below. (See <a class="local">'Clinical administration of DLI'</a> below.)</p><p class="headingAnchor" id="H4219683478"><span class="h2">Enhancement of chimerism</span><span class="headingEndMark"> — </span>DLI may enhance donor engraftment in the setting of mixed chimerism following HCT. In a single center study, DLI after T cell depletion with <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> or anti-thymocyte globulin achieved full donor chimerism in 67 percent of patients with mixed donor chimerism [<a href="#rid25">25</a>]. However, other experiences are not as favorable and in our experience DLI alone rarely results in improved chimerism. An alternative is to combine <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">pentostatin</a> with DLI, although definitive studies are lacking [<a href="#rid34">34</a>].</p><p>We suggest <strong>not</strong> using DLI solely to enhance engraftment in the setting of mixed chimerism, unless there is evidence of relapsed disease, as discussed below. (See <a class="local">'Cautions regarding DLI'</a> below.)</p><p class="headingAnchor" id="H1112077615"><span class="h2">Clinical administration of DLI</span><span class="headingEndMark"> — </span>No prospective studies have directly compared DLI regimens for treatment of relapsed hematologic malignancies. There is no consensus regarding the optimal dose or timing of DLI, or the method for collection or processing of infusion products. Clinical application of DLI varies in different transplant centers.</p><p>Outside of the context of a clinical trial, we favor administration of DLI upon detection of molecular relapse (ie, MRD) rather than waiting for emergence of hematologic/clinical relapse. Selection of dose should consider the clinical setting (ie, clinical versus molecular relapse) and the doses that were used in trials of DLI in patients with that particular malignancy. As examples, for molecular relapse we treat with ≥1 x 10<sup>6</sup> CD3+ cells/kg, while for clinical relapse we generally treat with 1 to 3 x 10<sup>7</sup> CD3+ cells/kg. We treat with unmanipulated T cells, collected by apheresis, and administered in a single infusion. Use of DLI for CML and AML is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4494.html" rel="external">"Hematopoietic cell transplantation in chronic myeloid leukemia", section on 'Donor lymphocyte infusion'</a> and  <a class="medical medical_review" href="/z/d/html/4540.html" rel="external">"Treatment of relapsed or refractory acute myeloid leukemia", section on 'Donor lymphocyte infusion'</a>.)</p><p>Patients who respond to DLI usually demonstrate a clinical response within two to three months, although a full response may take one year or longer [<a href="#rid14">14</a>]. A second DLI infusion may be administered if no clinical response is seen within three months.</p><p>We favor administration of DLI upon detection of measurable residual disease (MRD), rather than waiting for emergence of hematologic/clinical relapse. In theory, DLI may be more effective when there is less disease burden, thereby permitting a lower dose DLI, which has been associated with reduced risk of GVHD. Some experts advocate the use of DLI upon detection of MRD [<a href="#rid21">21</a>], while others await clinical relapse [<a href="#rid35">35</a>]. A decision regarding the timing of DLI is influenced by the responsiveness of the underlying disease to DLI, the risk of GVHD, institutional practice, and goals and fears of the patient and clinician.</p><p>In the setting of hematologic/clinical relapse, we generally treat with salvage chemotherapy to reduce the burden of disease prior to DLI. We do not treat with concurrent chemotherapy and DLI, because it is associated with increased toxicity, excess treatment-related mortality, and no evidence of improved survival [<a href="#rid35">35</a>]. Chemotherapy regimens to reduce the burden of relapsed disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4540.html" rel="external">"Treatment of relapsed or refractory acute myeloid leukemia"</a> and  <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults"</a>.)</p><p>Techniques to deplete or enrich specific lymphocyte subsets or to manipulate the donor infusion product are considered experimental and we suggest <strong>not</strong> using them outside of the context of a clinical trial. Such experimental approaches are discussed below. (See <a class="local">'Investigational approaches'</a> below.)</p><p class="headingAnchor" id="H1185397292"><span class="h3">Cautions regarding DLI</span><span class="headingEndMark"> — </span>Toxicity of DLI is significant, and certain cautions should be considered prior to proceeding, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GVHD</strong> – DLI should be avoided in patients with steroid-resistant GVHD (ie, ≥grade 2) because of the significant risk of further exacerbating this condition. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoplasia</strong> – Chimerism studies should be performed before DLI because of the risk of bone marrow hypoplasia in patients who have converted to host (rather than donor) chimerism. (See <a class="local">'Hypoplasia'</a> above.)</p><p></p><p class="bulletIndent1">DLI should not be used (or used only with extreme caution) in patients who have converted to host chimerism (ie, graft failure). There is no consensus, but various experts suggest ≥10 percent to ≥50 percent donor chimerism as a threshold for use of DLI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft failure</strong> – We suggest <strong>not</strong> using DLI solely for the purpose of enhancing engraftment in the setting of mixed chimerism, unless there is evidence of relapsed disease, because of the risk of exacerbating GVHD.</p><p></p><p class="headingAnchor" id="H2472925296"><span class="h1">CHECKPOINT INHIBITORS</span><span class="headingEndMark"> — </span>Inhibition of negative regulators of T cell-mediated immunity (eg, PD-1/PD-L1, CTLA-4) can achieve remission of hematologic malignancies that relapse after HCT. Regulation of the immune response after HCT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation"</a>.)</p><p>As an example, the checkpoint inhibitor <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> achieved complete response (CR) in 23 percent, partial response (PR) in 9 percent, and decreased tumor burden in 27 percent of 22 patients with relapsed hematologic malignancies; four patients sustained a response for more than one year [<a href="#rid36">36</a>]. Immune-related adverse events, including one death, were observed in 21 percent, and GVHD that precluded further administration of ipilimumab was observed in 14 percent. In another study, treatment with PD-1 blockade after allogeneic HCT was frequently complicated by severe and treatment-refractory GVHD [<a href="#rid37">37</a>].</p><p>Blockade of the PD-1/PD-L1 interaction may relieve T cell "exhaustion" (inhibition) exerted by cancer cells on CD8+ T cells against minor histocompatibility antigens. Blockade of this pathway has been combined with an experimental vaccine strategy for multiple myeloma [<a href="#rid38">38</a>]. Use of PD-1 blockade in Hodgkin lymphoma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma", section on 'PD-1 blockade'</a>.)</p><p class="headingAnchor" id="H1826162920"><span class="h1">CHIMERIC ANTIGEN RECEPTOR T CELLS</span><span class="headingEndMark"> — </span>Chimeric antigen receptor T cells (CAR-T cells) are a form of genetically modified autologous immunotherapy that can be directed at tumor antigens.</p><p>CAR-T cells are effective for relapsed leukemias and lymphomas after HCT. Efficacy and toxicity of <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">tisagenlecleucel</a> and <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">axicabtagene ciloleucel</a> for treatment of relapsed acute lymphoblastic leukemia and diffuse large B cell lymphoma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4518.html" rel="external">"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'CAR-T'</a> and  <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Chimeric antigen receptor T cell therapy'</a>.)</p><p>CAR-T cells are undergoing investigation for other hematologic malignancies such as chronic lymphocytic leukemia (CLL). (See  <a class="medical medical_review" href="/z/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Investigational therapies'</a>.)</p><p class="headingAnchor" id="H2829698230"><span class="h1">INTERLEUKIN-2</span><span class="headingEndMark"> — </span>We advise that the cytokine interleukin-2 (IL-2) should <strong>not</strong> be used for relapse after HCT outside of the context of a clinical trial. IL-2 is approved by the US Food and Drug Administration to promote survival, expansion, and activation of lymphocytes, but there are concerns about its potential suppression of graft-versus-tumor (GVT) because it preferentially stimulates Tregs.</p><p>No prospective controlled studies of IL-2 have demonstrated improved clinical outcomes after HCT, and it may worsen toxicity [<a href="#rid39">39-42</a>]. IL-2 was associated with inferior rates of disease-free survival and overall survival at three years in a prospective study in which patients with measurable residual disease (MRD) after allogeneic HCT for acute leukemia were treated with either DLI or IL-2 (if they did not have an available donor) [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H367419762"><span class="h1">INVESTIGATIONAL APPROACHES</span><span class="headingEndMark"> — </span>Various novel strategies are under investigation to enhance donor-mediated graft-versus-tumor (GVT) effect (to prevent or control disease relapse) and/or reduce graft-versus-host disease (GVHD) in patients who relapse after allogeneic HCT.</p><p>While many of these approaches are promising, we suggest <strong>not</strong> using them at present, outside of the context of a clinical trial.</p><p class="headingAnchor" id="H3118706207"><span class="h2">DLI plus targeted therapy</span><span class="headingEndMark"> — </span>Donor lymphocyte infusion (DLI) has been combined with targeted agents to control residual disease after allogeneic HCT.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>AML/CML:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In older patients with relapse of acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), 5-azacitidine followed by DLI achieved responses in 66 percent, including patients with adverse-risk cytogenetic findings [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>DLI in combination with the tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> for <em>FLT3</em>-ITD mutant AML was associated with substantial responses but significant GVHD, cytopenias, and hand-foot syndrome [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low dose DLI (0.5 to 1 x 10<sup>7</sup> mononuclear cells/kg) in combination with interferon alfa achieved remissions with acceptable levels of GVHD for chronic phase CML that relapsed after allogeneic HCT [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple myeloma</strong> – <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a> and <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> have been administered together with DLI in patients with residual multiple myeloma after allogeneic HCT and appeared to enhance responses without exacerbating GVHD [<a href="#rid46">46,47</a>].</p><p></p><p class="headingAnchor" id="H3026968200"><span class="h2">Manipulated DLI grafts</span><span class="headingEndMark"> — </span>Techniques for manipulation of the donor product (eg, enrichment, depletion, activation) are considered experimental and require further study before they can be widely applied for DLI.</p><p class="headingAnchor" id="H2508014764"><span class="h3">Lymphocyte depletion/enrichment</span><span class="headingEndMark"> — </span>Enrichment and/or depletion of specific lymphocyte subsets to enhance GVT or lessen GVHD are undergoing investigation.</p><p>Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>T lymphocyte subsets</strong> – Fractionation of the donor product has been used to enrich CD4+ T cells or deplete CD8+ T cells. As an example, in a study of patients who underwent reduced intensity conditioning (RIC) allogeneic HCT using <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, DLI with CD8-depleted product accelerated immune reconstitution, improved donor engraftment, and was not associated with significant GVHD [<a href="#rid48">48</a>]. Other studies have also shown safety of CD4-enriched and/or CD8-depleted DLI treatment [<a href="#rid31">31,49</a>].</p><p></p><p class="bulletIndent1">DLI with CD25/Treg-depleted product was capable of inducing GVT tumor responses without excessive GVHD [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">Enrichment of memory T cells (CD8+, CD44<sup>high</sup>) is undergoing investigation as a means of establishing an in vivo reservoir of functional antigen-specific T cells [<a href="#rid24">24,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural killer (NK) cells</strong> – NK cells exert potent GVT effects without initiating GVHD, and act through a variety of cytokine receptors, and activating or inhibitory receptors [<a href="#rid52">52</a>]. Alloreactive haploidentical NK cells can be safely administered and may reduce leukemia progression without an increase in GVHD or transplantation-related mortality [<a href="#rid53">53-57</a>].</p><p></p><p class="headingAnchor" id="H2775576059"><span class="h3">Ex vivo activation</span><span class="headingEndMark"> — </span>Activation of DLI effectors prior to infusion may enhance GVT.</p><p>Examples of clinical studies of ex vivo activated lymphocytes include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytokine-induced killer (CIK) cells</strong> – Ex vivo culture of lymphocytes with interferon gamma, IL-2, and anti-CD3 creates CIKs, which are cytotoxic T cells that recognize targets through the C-type lectin receptor, NKG2D [<a href="#rid58">58</a>]. CIKs can kill autologous tumor targets in patients with a variety of malignancies [<a href="#rid59">59,60</a>]. Allogeneic CIK cells achieved response rates of 30 percent with acceptable toxicity in patients with relapsed AML [<a href="#rid61">61</a>]. CIKs have also been examined as DLI after autologous and allogeneic HCT for CML and lymphomas [<a href="#rid62">62-64</a>]. These cells have been used for construction of chimeric antigen receptor (CAR)-T cells, with encouraging results [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural killer (NK) cells</strong> – IL-15 is a cytokine that can increase NK and T cell proliferation and activation without stimulating Tregs, but it has a short half-life in vivo [<a href="#rid66">66</a>]. ALT-803 is an engineered IL-15 superagonist complex with an extended half-life that can mimic the physiologic action of IL-15 [<a href="#rid67">67,68</a>]. In a phase I study in patients with relapsed hematologic malignancies after allogeneic HCT, ALT-803 achieved clinical responses in 19 percent of evaluable patients (including one complete remission lasting seven months) and was well tolerated with no dose-limiting toxicities or exacerbation of GVHD [<a href="#rid69">69</a>]. ALT-803 resulted in NK cell expansion and activation with minimal changes in CD4+ T cells and Tregs. NK cells have also been used for generation of CAR-NK cells with encouraging results in early phase clinical trials [<a href="#rid70">70</a>].</p><p></p><p class="headingAnchor" id="H1708221858"><span class="h3">Modified leukocytes</span><span class="headingEndMark"> — </span>Modification of T cells by creation of chimeric antigen receptor T cells (CAR-T cells) is discussed above. (See <a class="local">'Chimeric antigen receptor T cells'</a> above.)</p><p>Donor T cells have been genetically altered to contain a fusion caspase 9 protein that could induce apoptosis upon exposure to a synthetic dimerizing drug [<a href="#rid71">71</a>]. Administration of the dimerizing drug to four patients who developed GVHD eliminated 90 percent of the modified T cells within 30 minutes and resulted in resolution of the GVHD within 48 hours.</p><p class="headingAnchor" id="H3096959960"><span class="h2">HLA-mismatched HCT</span><span class="headingEndMark"> — </span>In most centers, a complete match at the HLA-A, HLA-B, HLA-C, and HLA-DR loci is preferred for allogeneic donors, because mismatches are associated with a higher risk of severe GVHD, despite the possible induction of GVT. (See  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p>Transplantation across HLA barriers in the setting of a nonmyeloablative (NMA) conditioning regimen (with or without DLI) may create mixed chimerism with potent GVT without induction of severe GVHD [<a href="#rid72">72,73</a>]. In one study of five patients with refractory non-Hodgkin lymphoma, the use of such a strategy was associated with complete and partial clinical remission in two patients and neither patient developed GVHD [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation", section on 'Mismatched related donors'</a>.)</p><p>Haploidentical grafts should trigger alloreactivity based on HLA class I disparity between donor and recipient via killer immunoglobulin-like receptors (KIR) on NK cells [<a href="#rid74">74</a>]. NK cells can persist and expand in vivo in the setting of haploidentical HCT [<a href="#rid53">53</a>], but a retrospective analysis identified no clear advantage associated with KIR ligand incompatibility [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H1207218460"><span class="h2">Cancer vaccines</span><span class="headingEndMark"> — </span>Cancer vaccines may provide a strategy to disrupt tumor-associated tolerance and activate and/or selectively expand tumor specific immunity. The post-transplant setting is a promising platform for vaccination because greater immune responsiveness may result from depletion of inhibitory accessory cells.</p><p>Dendritic cells (DC) are antigen-presenting cells that play a major role in the induction of an immune-mediated response [<a href="#rid76">76</a>]. DCs can be obtained from the peripheral blood and expanded ex vivo.</p><p>Whole cell-based strategies have created fusions of DCs with tumor cells. As an example, one study treated six patients with multiple myeloma with reduced intensity conditioning (RIC) allogeneic HCT and a partial T cell-depleted graft followed by DLI and DC vaccination [<a href="#rid77">77</a>]. DC vaccination was associated with limited toxicity, and none of these patients developed GVHD.</p><p>In a phase I clinical trial, patients with high-risk AML or MDS were immunized with irradiated, autologous, granulocyte-macrophage colony-stimulation factor (GM-CSF)-secreting tumor cells early after allogeneic NMA HCT [<a href="#rid78">78</a>]. Vaccination elicited local and systemic reactions without an increase in GVHD, and 9 of 10 subjects who completed vaccination achieved durable complete remissions (median follow-up 26 months).</p><p class="headingAnchor" id="H2443247150"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120313.html" rel="external">"Society guideline links: Management of Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Immunotherapy takes advantage of the graft-versus-tumor (GVT) effect to prevent or treat relapse of hematologic malignancies following allogeneic hematopoietic cell transplantation (HCT). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Donor lymphocyte infusion (DLI) can induce GVT and achieve durable remissions in some patients who relapse after allogeneic HCT. DLI is mediated by immune effector cells (<a class="graphic graphic_table graphicRef52815" href="/z/d/graphic/52815.html" rel="external">table 1</a>), including various T cells and natural killer (NK) cells, primarily by relieving T cell "exhaustion." (See <a class="local">'Donor lymphocyte infusion (DLI)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Efficacy of DLI varies with the type and amount of the underlying malignancy, dose and type of lymphocytes that are infused, and factors related to the initial allogeneic HCT. Response rates are highest with chronic myeloid leukemia (CML), but other types of leukemia and lymphomas also respond to DLI. (See <a class="local">'Efficacy of DLI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who respond to DLI usually demonstrate a clinical response within two to three months, but a full response may take one year or longer. Responses to DLI can be durable, with some responses lasting for many years. (See <a class="local">'Time course of DLI response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimal dose and timing of DLI are not well defined and clinical practice varies by institution. Outside of the context of a clinical trial, we favor administration of DLI upon detection of molecular relapse, rather than waiting for emergence of hematologic/clinical relapse. Selection of dose should consider the clinical setting (ie, clinical versus molecular relapse) and doses that were used in trials of DLI in patients with that particular malignancy, as described above. (See <a class="local">'Clinical administration of DLI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major complications of DLI are graft-versus-host disease (GVHD) and myelosuppression/bone marrow hypoplasia. (See <a class="local">'Toxicity of DLI'</a> above.)</p><p></p><p class="bulletIndent1">For some patients, ongoing GVHD or increased risk of marrow hypoplasia (eg, due to loss of donor chimerism) may preclude use of DLI. (See <a class="local">'Cautions regarding DLI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other immunotherapy approaches for relapse after HCT include checkpoint inhibitors and chimeric antigen T cell receptors (CAR-T). (See <a class="local">'Checkpoint inhibitors'</a> above and <a class="local">'Chimeric antigen receptor T cells'</a> above.)</p><p></p><p class="bulletIndent1">We advise that interleukin-2 (IL-2) should <strong>not</strong> be used for relapse after HCT, outside of the context of a clinical trial, as discussed above. (See <a class="local">'Interleukin-2'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Experimental approaches to enhance donor-mediated GVT and/or reduce GVHD include combinations of DLI with targeted agents, manipulation of the DLI product before infusion, HLA-mismatched allogeneic HCT, and vaccination strategies, as described above. (See <a class="local">'Investigational approaches'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.</a></li><li><a class="nounderline abstract_t">Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300:1068.</a></li><li><a class="nounderline abstract_t">Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304:1529.</a></li><li><a class="nounderline abstract_t">Rubio MT, Moreira-Teixeira L, Bachy E, et al. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood 2012; 120:2144.</a></li><li><a class="nounderline abstract_t">Chaidos A, Patterson S, Szydlo R, et al. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 2012; 119:5030.</a></li><li><a class="nounderline abstract_t">Malard F, Labopin M, Chevallier P, et al. Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. Blood 2016; 127:1828.</a></li><li><a class="nounderline abstract_t">Christopher MJ, Petti AA, Rettig MP, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med 2018; 379:2330.</a></li><li><a class="nounderline abstract_t">Elmaagacli AH, Beelen DW, Trenn G, et al. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23:771.</a></li><li><a class="nounderline abstract_t">Mehta J, Powles R, Singhal S, et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996; 17:371.</a></li><li><a class="nounderline abstract_t">Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492.</a></li><li><a class="nounderline abstract_t">Bachireddy P, Hainz U, Rooney M, et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 2014; 123:1412.</a></li><li><a class="nounderline abstract_t">Claret EJ, Alyea EP, Orsini E, et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest 1997; 100:855.</a></li><li><a class="nounderline abstract_t">Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000; 106:705.</a></li><li><a class="nounderline abstract_t">Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010; 36:528.</a></li><li><a class="nounderline abstract_t">Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112:4371.</a></li><li><a class="nounderline abstract_t">Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712.</a></li><li><a class="nounderline abstract_t">Russell NH, Byrne JL, Faulkner RD, et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36:437.</a></li><li><a class="nounderline abstract_t">Porter DL, Collins RH Jr, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95:1214.</a></li><li><a class="nounderline abstract_t">Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26:769.</a></li><li><a class="nounderline abstract_t">Stern M, de Wreede LC, Brand R, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia 2014; 28:2235.</a></li><li><a class="nounderline abstract_t">Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119:3256.</a></li><li><a class="nounderline abstract_t">Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103:767.</a></li><li><a class="nounderline abstract_t">Yun HD, Waller EK. Finding the sweet spot for donor lymphocyte infusions. Biol Blood Marrow Transplant 2013; 19:507.</a></li><li><a class="nounderline abstract_t">Nikiforow S, Alyea EP. Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions. Hematology Am Soc Hematol Educ Program 2014; 2014:570.</a></li><li><a class="nounderline abstract_t">Krishnamurthy P, Potter VT, Barber LD, et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013; 19:562.</a></li><li><a class="nounderline abstract_t">Miller JS, Weisdorf DJ, Burns LJ, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007; 110:2761.</a></li><li><a class="nounderline abstract_t">Baba J, Watanabe S, Saida Y, et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 2012; 120:2417.</a></li><li><a class="nounderline abstract_t">Liga M, Triantafyllou E, Tiniakou M, et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biol Blood Marrow Transplant 2013; 19:75.</a></li><li><a class="nounderline abstract_t">Scarisbrick JJ, Dignan FL, Tulpule S, et al. A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant 2015; 50:62.</a></li><li><a class="nounderline abstract_t">Bar M, Sandmaier BM, Inamoto Y, et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant 2013; 19:949.</a></li><li><a class="nounderline abstract_t">Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91:3671.</a></li><li><a class="nounderline abstract_t">Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86:4337.</a></li><li><a class="nounderline abstract_t">Keil F, Haas OA, Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997; 89:3113.</a></li><li><a class="nounderline abstract_t">Bar M, Flowers MED, Storer BE, et al. Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 2018; 24:308.</a></li><li><a class="nounderline abstract_t">Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20:405.</a></li><li><a class="nounderline abstract_t">Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med 2016; 375:143.</a></li><li><a class="nounderline abstract_t">Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 2017; 130:221.</a></li><li><a class="nounderline abstract_t">Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011; 34:409.</a></li><li><a class="nounderline abstract_t">Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997; 89:3951.</a></li><li><a class="nounderline abstract_t">Stein AS, O'Donnell MR, Slovak ML, et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J Clin Oncol 2003; 21:615.</a></li><li><a class="nounderline abstract_t">Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86:1619.</a></li><li><a class="nounderline abstract_t">Thompson JA, Fisher RI, Leblanc M, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 2008; 111:4048.</a></li><li><a class="nounderline abstract_t">Lübbert M, Bertz H, Wäsch R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010; 45:627.</a></li><li><a class="nounderline abstract_t">De Freitas T, Marktel S, Piemontese S, et al. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2016; 96:629.</a></li><li><a class="nounderline abstract_t">Posthuma EF, Marijt EW, Barge RM, et al. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant 2004; 10:204.</a></li><li><a class="nounderline abstract_t">Kröger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009; 37:791.</a></li><li><a class="nounderline abstract_t">El-Cheikh J, Crocchiolo R, Furst S, et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol 2012; 40:521.</a></li><li><a class="nounderline abstract_t">Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007; 109:374.</a></li><li><a class="nounderline abstract_t">Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009; 113:4771.</a></li><li><a class="nounderline abstract_t">Nikiforow S, Kim HT, Daley H, et al. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica 2016; 101:1251.</a></li><li><a class="nounderline abstract_t">Wang X, Berger C, Wong CW, et al. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 2011; 117:1888.</a></li><li><a class="nounderline abstract_t">Caligiuri MA. Human natural killer cells. Blood 2008; 112:461.</a></li><li><a class="nounderline abstract_t">Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051.</a></li><li><a class="nounderline abstract_t">Curti A, Ruggeri L, D'Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118:3273.</a></li><li><a class="nounderline abstract_t">Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant 2014; 20:696.</a></li><li><a class="nounderline abstract_t">Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014; 123:3855.</a></li><li><a class="nounderline abstract_t">Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med 2016; 8:357ra123.</a></li><li><a class="nounderline abstract_t">Verneris MR, Karimi M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004; 103:3065.</a></li><li><a class="nounderline abstract_t">Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001; 7:216.</a></li><li><a class="nounderline abstract_t">Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002; 116:78.</a></li><li><a class="nounderline abstract_t">Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17:1679.</a></li><li><a class="nounderline abstract_t">Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11:181.</a></li><li><a class="nounderline abstract_t">Kumar AJ, Hexner EO, Frey NV, et al. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19:1094.</a></li><li><a class="nounderline abstract_t">Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 107:1325.</a></li><li><a class="nounderline abstract_t">Magnani CF, Gaipa G, Lussana F, et al. Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest 2020; 130:6021.</a></li><li><a class="nounderline abstract_t">Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015; 33:74.</a></li><li><a class="nounderline abstract_t">Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6:595.</a></li><li><a class="nounderline abstract_t">Rubinstein MP, Kovar M, Purton JF, et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A 2006; 103:9166.</a></li><li><a class="nounderline abstract_t">Romee R, Cooley S, Berrien-Elliott MM, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 2018; 131:2515.</a></li><li><a class="nounderline abstract_t">Gang M, Marin ND, Wong P, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood 2020; 136:2308.</a></li><li><a class="nounderline abstract_t">Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673.</a></li><li><a class="nounderline abstract_t">Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353:1755.</a></li><li><a class="nounderline abstract_t">Dey BR, McAfee S, Colby C, et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128:351.</a></li><li><a class="nounderline abstract_t">Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097.</a></li><li><a class="nounderline abstract_t">Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100:3825.</a></li><li><a class="nounderline abstract_t">Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100:2757.</a></li><li><a class="nounderline abstract_t">Levenga H, Schaap N, Maas F, et al. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant 2010; 16:320.</a></li><li><a class="nounderline abstract_t">Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 2009; 106:15825.</a></li></ol></div><div id="topicVersionRevision">Topic 3552 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135448" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Identical-twin bone marrow transplants for leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34792" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7015133" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22730537" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371885" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903546" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30380364" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10231138" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704689" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21739672" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : T cell exhaustion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357730" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9259585" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974024" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20381970" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029455" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Graft-versus-leukemia effects of transplantation and donor lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11023502" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15980879" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10666193" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11042659" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781016" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22337715" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12958064" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Graft-versus-leukemia reactions in allogeneic chimeras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23416853" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Finding the sweet spot for donor lymphocyte infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25696913" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266740" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17579184" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806892" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22871557" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25310308" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23523892" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573003" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492795" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129013" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032276" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786567" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27410923" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ipilimumab for Patients with Relapse after Allogeneic Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28468799" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21577144" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166832" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12586797" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7632972" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256325" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19718057" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26260140" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993886" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487069" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22446605" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940425" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19211934" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27354021" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21123821" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650461" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Human natural killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15632206" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791425" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24525278" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719405" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27655849" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070686" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11349808" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11841399" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664472" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15744236" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635453" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16269610" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32780725" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25403209" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868550" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757567" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463563" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614951" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22047558" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Inducible apoptosis as a safety switch for adoptive cell therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347989" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667537" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896281" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393440" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389740" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19835972" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717467" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
